Prednisolone Sodium Succinate (Canada)

This page contains information on Prednisolone Sodium Succinate for veterinary use.
The information provided typically includes the following:
  • Prednisolone Sodium Succinate Indications
  • Warnings and cautions for Prednisolone Sodium Succinate
  • Direction and dosage information for Prednisolone Sodium Succinate

Prednisolone Sodium Succinate

This treatment applies to the following species:
Manufacturer: Univet

DIN: 00553506

Active Ingredient(s): Each mL (when mixed) contains:

Prednisolone sodium succinate

10.00 mg

Sodium biphosphate anhydrous

0.075 mg

Dried sodium phosphate

0.81 mg

Lactose hydrous

19.6 mg

Tyloxapol

4.9 mg

Chlorobutanol anhydrous

3.0 mg

Water for injection

q.s. to 1 mL

Prednisolone Sodium Succinate Indications

PREDNISOLONE SODIUM SUCCINATE is indicated for use in situations in which a rapid and intense adrenal glucocorticoid and/or anti-inflammatory effect is necessary. If the intravenous route is impractical, the intramuscular route may be used.

Inflammatory Conditions: As with other adrenal steroids, PREDNISOLONE SODIUM SUCCINATE has been found useful in alleviating lameness associated with acute localized and generalized arthritic conditions in horses, dogs and cats. PREDNISOLONE SODIUM SUCCINATE has been used successfully to treat bursitis, carpitis, tendinitis, and myositis. Remission of the symptoms may be permanent or the symptoms may recur, depending upon the cause and the extent of structural degeneration.

Generalized muscular soreness, stiffness, depression, and anorexia as a result of overtraining, shipping, unusual physical exertion, etc., respond to PREDNISOLONE SODIUM SUCCINATE.

Allergic Reactions: PREDNISOLONE SODIUM SUCCINATE is beneficial in treating acute hypersensitivity reactions resulting from treatment with a sensitizing drug or exposure to other allergenic agents. The usual manifestations are anaphylactic reactions and urticaria. Less severe allergic manifestations, such as atopic and contact dermatitis, summer eczema, and conjunctivitis also may be treated. The response is usually rapid and complete, although in severe cases with extensive lesions, more prolonged adrenocorticoid therapy and other appropriate treatment may be indicated.

Overwhelming Infections with Severe Toxicity: In animals moribund from overwhelmingly severe infections for which specific antibacterial therapy is available (e.g., critical pneumonia, peritonitis, endometritis, mastitis), intense PREDNISOLONE SODIUM SUCCINATE therapy may aid in correcting the circulatory defect by counteracting the responsible inflammatory changes, thereby permitting the antibacterial agent to exert its full effect. As supportive therapy, the product combats the stress and improves the general attitude of the animal being treated. All necessary procedures for the establishment of a bacterial diagnosis should be carried out whenever possible before institution of therapy. In the presence of infection, PREDNISOLONE SODIUM SUCCINATE should be administered for the shortest possible time compatible with the maintenance of an adequate clinical response, and antibacterial therapy should be continued for at least three days after the hormone has been withdrawn. Combined hormone and antibacterial therapy does not obviate the need for indicated surgical treatment.

Shock: For dogs, intravenous PREDNISOLONE SODIUM SUCCINATE is indicated in the prevention and treatment of adrenal failure and shock-like states occurring in association with severe injury or other trauma, emergency surgery, anaphylactic reactions and elective surgery in poor surgical risks. The hormone is recommended as an adjunct to standard methods of combating shock, including the use of plasma expanders. Because of interrelated physiologic activities, the beneficial effects may not be exhibited until all such procedures have been employed. PREDNISOLONE SODIUM SUCCINATE is an invaluable emergency kit drug.

Other Indications: PREDNISOLONE SODIUM SUCCINATE has been found useful as supportive therapy in the treatment of stress-induced exhaustion, rattlesnake bite, toxaemia, inflammatory ocular conditions and other stress conditions. Its employment in the treatment of these conditions is recommended as a measure supportive to standard procedures and time honoured treatments and will aid in the recovery of the animal.

Dosage and Administration

The intravenous administration is of particular value in treating acute laminitis (founder) in horses. It is important that the condition be detected early so that therapy may be instituted before there is irreparable damage to the laminae. It may be given at intervals of 12 to 24 hours, depending upon the response. Correction and/or treatment of the etiological factors is imperative and routine local antiphlogistic measures should be employed.

Horses: The dosage for horses is 50 to 100 mg as an initial dose. This may be given intravenously over a period of one-half (1/2) to one (1) minute, or intramuscularly, and may be repeated in inflammatory allergic or other stress conditions, at intervals of 12, 24, or 48 hours, depending upon the size of the animal, the severity of the condition, and the response to treatment.

Dogs: The usual intravenous dose in shock and shock-like states ranges from 2.5 to 5 mg per lb. of body weight as an initial dose, followed by equal maintenance doses at 1-, 3-, 6-, or 10-hour intervals as determined by the condition of the animal.

Dogs and Cats: The intramuscular dose in inflammatory, allergic, and less severe stress conditions, where immediate effect is not required, is usually 1 to 5 mg ranging upwards to 30 to 50 mg in large breeds of dogs. This may be repeated in 12 to 24 hours and continued for three (3) to five (5) days, if necessary. If a permanent corticosteroid effect is required, oral therapy with prednisolone tablets may be substituted as soon as possible. When therapy is to be withdrawn after prolonged corticosteroid administration, the daily dose should be reduced gradually over a number of days, in a stepwise fashion.

Note: If desired PREDNISOLONE SODIUM SUCCINATE may be incorporated into infusion solutions, but must not be added to calcium infusion solutions. If the solution becomes cloudy after reconstituting, it should not be used intravenously.

Contraindication(s): Except when used for emergency therapy, PREDNISOLONE SODIUM SUCCINATE is contraindicated in animals with tuberculosis, Cushingoid syndrome, and peptic ulcer. Existence of congestive heart failure, diabetes, chronic nephritis, and osteoporosis are relative contraindications. In the presence of infection, appropriate antibacterial agents should also be administered and should be continued for at least three days after the discontinuance of the hormone and disappearance of all signs of infection. Do not use in viral infections.

Caution(s): PREDNISOLONE SODIUM SUCCINATE may suppress systemic manifestations such as fever and also signs of toxaemia. In some instances this alteration of the inflammatory reaction may be beneficial, however, it may also mask the signs of infection and tend to facilitate the spread of micro-organisms. In infections characterized by overwhelming toxicity, PREDNISOLONE SODIUM SUCCINATE therapy in conjunction with indicated antibacterial therapy is effective in reducing mortality and morbidity. It is essential that the causative organism be known and an effective antibacterial agent be administered concurrently. The injudicious use of adrenal hormones in animals with infections can be hazardous.

Warning(s): Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the third trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

This drug must not be used in horses that are to be slaughtered for use in food.

Side Effects

The therapeutic use of PREDNISOLONE SODIUM SUCCINATE is unlikely to cause an undesired accentuation of metabolic effects. However, if continued corticosteroid therapy is anticipated, a high protein intake should be provided to keep the animal in positive nitrogen balance. A retardant effect on wound healing has not been encountered, but such a possibility should also be considered when it is used in conjunction with surgery. Euphoria, or an improvement of attitude, and increased appetite are usual manifestations.

Undesirable effects of adrenocorticoid administration are sodium and water retention, potassium loss, glycosuria, hyperglycaemia, polyuria and polydipsia.

Presentation: 10 mL monovials.

NAC No.: 12290110

UNIVET PHARMACEUTICALS LTD.
50 STEELES AVE., UNIT #1, MILTON, ON, L9T 2Y5
Telephone:   905-876-1990
Order Desk:   800-268-5069
Fax:   905-878-5311
Website:   www.univetpharm.com
Email:   univet@univetpharm.com
Every effort has been made to ensure the accuracy of the Prednisolone Sodium Succinate information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-09-05

(web5)